Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inhibition of interleukin-1 release by IX 207-887.

J Schnyder1, P Bollinger, T Payne

  • 1Sandoz Research Institute Berne Ltd., Switzerland.

Agents and Actions
|June 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of brain and spinal MRI measures in a common domain to investigate directional neurodegeneration in motor neuron disease.

Journal of neurology·2022
Same author

The utilisation of vascular limb salvage services in the assessment and management of chronic limb-threatening ischaemia and diabetic foot ulceration: A systematic review.

Diabetes/metabolism research and reviews·2020
Same author

Transformation and regeneration of Lobelia erinus using Agrobacterium tumefaciens.

Plant cell reports·2019
Same author

Account of a New Poultice.

The Medical and physical journal·2018
Same author

Use of more than one electronic medical record system within a single health care organization.

Applied clinical informatics·2013
Same author

Modification of a draw-over vaporizer for use with sevoflurane.

British journal of anaesthesia·2012

Compound IX 207-887 effectively inhibits interleukin-1 (IL-1) release from immune cells, offering a novel therapeutic approach for inflammatory conditions like rheumatoid arthritis.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Interleukin-1 (IL-1) plays a critical role in mediating inflammatory responses, particularly in conditions like rheumatoid arthritis.
  • Developing agents that specifically inhibit IL-1 release is a key therapeutic strategy for managing inflammatory diseases.

Purpose of the Study:

  • To investigate the mechanism of action of Compound IX 207-887 as a novel antiarthritic agent.
  • To determine if Compound IX 207-887 inhibits the release of biologically active and immunoreactive IL-1 from immune cells.

Main Methods:

  • Assessed IL-1 activity using four independent assay systems: metalloproteinase-release from chondrocytes, thymocyte proliferation assay, RIA, and ELISA.
  • Monitored IL-1 levels in conditioned media, homogenates, and lysates of human monocytes and mouse peritoneal macrophages.

Related Experiment Videos

  • Evaluated the effect of Compound IX 207-887 on the release of other monokines (IL-6, TNF-alpha) and lysozyme.

    • Main Results:

    • Compound IX 207-887 significantly reduced both biologically active and immunoreactive IL-1 in culture media.
    • IL-1 levels in homogenates or lysates were largely unaffected, indicating inhibition of release rather than intracellular effects.
    • The release of other tested monokines and lysozyme was only marginally influenced, suggesting specificity for IL-1 release.

    Conclusions:

    • Compound IX 207-887 is a novel inhibitor of IL-1 release.
    • Its therapeutic potential in rheumatoid arthritis and other inflammatory conditions warrants further investigation.